SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Investment Chat Board Lawsuits -- Ignore unavailable to you. Want to Upgrade?


To: Jeffrey S. Mitchell who wrote (3708)9/17/2002 2:14:50 PM
From: afrayem onigwecher  Read Replies (2) | Respond to of 12465
 
John O'Quinn to Represent Biotech Firm in $250 Million Case Against Alleged Stock Manipulators

TUESDAY , SEPTEMBER 17, 2002 08:31 AM

MONTGOMERY, Texas, Sep 17, 2002 /PRNewswire-FirstCall via COMTEX/ -- Endovasc Ltd., Inc. (OTC Bulletin Board: ENVC) announced on Friday that the famous trial attorney, John M. O'Quinn, who has successfully sued tobacco companies, pharmaceutical companies, and breast implant manufacturers, had accepted the company's case for damages resulting from what Endovasc believes has been the manipulation of its stock. John O'Quinn was named one of the Nation's Top 10 Litigators and one of the 100 Most Influential Lawyers in America by the National Law Journal.

The company received an overwhelming amount of investor inquiries in response to its press release on Friday and would like to provide additional details on the case against stock manipulators.

"We are suing the alleged stock manipulators for $250 million. Even though the lawsuit is sizable, Endovasc is very fortunate, because John O'Quinn has agreed to be compensated on a results-only basis, i.e., on contingency. We believe that this clearly reflects Mr. O'Quinn's belief in the merits of our suit," says Dr. David P. Summers, Chairman and CEO of Endovasc.

"This lawsuit was filed on behalf of our shareholders who have been robbed by market manipulators and naked short-sellers, in an effort to restore value to our real investors and long term shareholders," adds Summers.

John O'Quinn and James W. "Wes" Christian represent several other bulletin board companies in their claims for damages against alleged stock manipulators. The cases claim alleged SEC 10b-5 violations, stock manipulation and fraudulent misrepresentation by alleged "investors" whose true intent allegedly was to drive down the company's stock prices through short-selling in order to receive much greater amounts of the company's shares when converting from preferred stock, debenture, or other convertible provision in financing deals with targeted bulletin board companies.

Endovasc Ltd., Inc., established in 1996, is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. The Company's pipeline of products and processes include: Liprostin(TM), ANGIOGENIX(TM) (Nicotine Receptor Agonist), PROStent(TM) stent-coating technology, and a biodegradable resorbable stent prosthesis.

The foregoing statements are made under the "Safe Harbor" Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements that involve risks and uncertainties that may not be evident at the time of this release. For more information about Endovasc, please visit www.endovasc.com . (Investor questions and requests for materials can be submitted online.)

MAKE YOUR OPINION COUNT - Click Here
tbutton.prnewswire.com

SOURCE Endovasc Ltd., Inc.

CONTACT: Investor Relations, Endovasc Ltd., Inc., +1-936-448-2222, fax,
+1-936-582-2250, InvestorRelations@endovasc.com

URL: endovasc.com



To: Jeffrey S. Mitchell who wrote (3708)9/18/2002 2:31:40 PM
From: StockDung  Read Replies (1) | Respond to of 12465
 
re:MARK E. RICE D/B/A PRIMEX CAPITAL, et al., SECURITIES AND EXCHANGE COMMISSION
LITIGATION RELEASE NO. 17732 / September 17, 2002
SECURITIES AND EXCHANGE COMMISSION v. MARK E. RICE D/B/A PRIMEX CAPITAL, et al., Civil Action No. H:02CV00636 (USDC S.D. Texas, September 11, 2002)

The Commission announced today that on September 11, 2002, the Honorable Vanessa Gilmore, United States District Court Judge for the Southern District of Texas located in Houston, entered a final judgment by default against Mark E. Rice of Sugar Land, Texas who did business under the name Primex Capital. The Court ordered Rice to repay his illegal trading profits totaling $900,367 which he obtained through his manipulation of the securities of four micro-cap companies, and prejudgment interest on those amounts of $184,755.20. Rice is jointly and severally liable with two companies for a portion of the $900,367 and interest. The Court also ordered Rice to pay civil penalties of $440,000, which consists of four $110,000 penalties, one for each of the four companies whose stock he manipulated.

The Commission alleged in its complaint filed on February 25, 2002 that between September 1999 and July 2000, Rice carried out "pump and dump" schemes to manipulate the stock of four micro-cap companies: Portalzone.com, Inc., which later changed its name to Status Wines of Tuscany, Inc. (Portalzone); Rockport Healthcare Group, Inc.; Global Connections, Inc.; and Pinnacle Business Management, Inc. The complaint alleged that Rice had issued unsolicited fraudulent "spam" e-mail messages, press releases and other promotional materials about the four companies and then engaged in manipulative trading in the stock of those companies when the price of the stocks increased because of the false statements. According to the Commission's complaint, Rice, and Portalzone in various press releases issued by the company, made false statements about the development of Portalzone's product purportedly an advanced Internet search engine, the company's revenue sources and business relationships with third parties, as well as Rice's stock-picking track record and trading intentions. The Commission's complaint alleged that Rice used two companies, relief defendants Primex (USA), Inc. (Primex), a Nevada corporation, and Applegate Sentry, S.A. (Applegate) a Bahamian corporation, to hide his sales of unregistered stock of three of the four companies into the market inflated by his false statements. Together, Rice and the two companies obtained illegal profits of $900,367.

Previously on March 5, 2002, the Court permanently enjoined Rice, based on his consent, from future violations of the securities registration provisions of Sections 5(a), and 5(c) of the Securities Act of 1933 (Securities Act), the anti-fraud provisions of Section 17(a) of the Securities Act and Section 10(b) of the Securities Exchange Act of 1934 (Exchange Act) and Rule 10b-5 thereunder, and the anti-manipulation provisions of Regulation M, Rule 101. On August 20, 2002, the Court also permanently enjoined Portalzone, which is now known as Status Wines of Tuscany, from violating the anti-fraud provisions of Section 10(b) of the Exchange Act, and Rule 10b-5. On June 26, 2002, the Court ordered relief defendants Primex and Applegate Sentry to disgorge their illegal trading profits of $759,174 and $51,665 respectively plus prejudgment interest on those amounts. Rice is jointly and severally liable with Primex and Applegate Sentry to repay the amounts of profits and prejudgment interest assessed against the two companies. For additional information see Litigation Releases 17377 ( February 25, 2002) and 17414 (March 14, 2002).



sec.gov

--------------------------------------------------------------------------------
Home | Previous Page Modified: 09/18/2002